Novo Nordisk Shares Outstanding 2006-2020 | NVO

Novo Nordisk shares outstanding history from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novo Nordisk shares outstanding for the quarter ending June 30, 2020 were 2.345B, a 1.6% decline year-over-year.
  • Novo Nordisk 2019 shares outstanding were 2.379B, a 1.89% decline from 2018.
  • Novo Nordisk 2018 shares outstanding were 2.424B, a 2.17% decline from 2017.
  • Novo Nordisk 2017 shares outstanding were 2.478B, a 2.23% decline from 2016.
Novo Nordisk Annual Shares Outstanding
(Millions of Shares)
2019 2,379
2018 2,424
2017 2,478
2016 2,535
2015 2,578
2014 2,630
2013 2,694
2012 2,758
2011 2,851
2010 2,927
2009 2,996
2008 3,103
2007 3,159
2006 3,229
2005 3,293
Novo Nordisk Quarterly Shares Outstanding
(Millions of Shares)
2020-06-30 2,345
2020-03-31 2,355
2019-12-31 2,379
2019-09-30 2,373
2019-06-30 2,384
2019-03-31 2,395
2018-12-31 2,424
2018-09-30 2,419
2018-06-30 2,431
2018-03-31 2,442
2017-12-31 2,478
2017-09-30 2,469
2017-06-30 2,484
2017-03-31 2,500
2016-12-31 2,535
2016-09-30 2,531
2016-06-30 2,541
2016-03-31 2,550
2015-12-31 2,578
2015-09-30 2,572
2015-06-30 2,584
2015-03-31 2,604
2014-12-31 2,630
2014-09-30 2,622
2014-06-30 2,637
2014-03-31 2,653
2013-12-31 2,694
2013-09-30 2,682
2013-06-30 2,703
2013-03-31 2,724
2012-12-31 2,758
2012-09-30 2,739
2012-06-30 2,762
2012-03-31 2,803
2011-12-31 2,810
2011-09-30 2,841
2011-06-30 2,869
2011-03-31 2,884
2010-12-31 2,888
2010-09-30 2,912
2010-06-30 2,945
2010-03-31 2,965
2009-12-31 2,976
2009-09-30 3,007
2009-06-30 3,015
2009-03-31 3,064
2008-12-31 3,072
2008-09-30 3,093
2008-06-30 3,118
2008-03-31 3,132
2007-12-31 3,148
2007-09-30 3,182
2007-06-30
2007-03-31 3,191
2006-12-31 3,194
2006-09-30 3,247
2006-06-30 3,233
2006-03-31 3,250
2005-12-31 3,232
2005-09-30 3,275
2005-06-30 3,315
2005-03-31 3,320
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $160.762B $18.296B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $380.891B 18.15
Roche Holding AG (RHHBY) Switzerland $306.127B 0.00
Merck (MRK) United States $210.306B 15.01
Pfizer (PFE) United States $198.714B 12.42
Novartis AG (NVS) Switzerland $197.515B 15.36
AbbVie (ABBV) United States $151.617B 9.24
Eli Lilly (LLY) United States $142.332B 21.72
AstraZeneca (AZN) United Kingdom $142.162B 27.64
Sanofi (SNY) $127.185B 15.12
GlaxoSmithKline (GSK) United Kingdom $93.769B 12.30
Bayer (BAYRY) Germany $59.273B 8.54
H Lundbeck (HLUYY) Denmark $6.418B 11.15
Innoviva (INVA) United States $1.091B 5.22